CCL5 and chronic kidney disease: Although our observation of impaired thrombus formation suggests at first sight a CKD-mediated inhibition of platelet function that fits the hemorrhagic phenotype, the increase in plasma soluble GPVI and 11-dehydro TXB2 levels, and the decreased platelet granule numbers and granule protein content of CCL5 in CKD rather point to prior platelet activation.